Latest Content

First Patient with Colon Cancer Dosed in a Phase 2 Study of TCMCB07

April 18th 2025, 3:00pm

By Spencer Feldman

Article

The first patient has received TCMCB07 in a phase 2 trial to prevent weight loss in patients with metastatic colorectal cancer undergoing chemotherapy.

Radiation Delay in NSCLC May Aid Outcomes, But Raises Toxicity Risks

April 18th 2025, 1:00pm

By Alex Biese

Article

Deferring upfront CNS-directed radiation in EGFR-variant and ALK-positive NSCLC may improve outcomes but raises treatment-related toxicity risks.

Radiation Therapy Now More Targeted and Tolerable in GI Cancer

April 17th 2025, 9:00pm

By Spencer Feldman

Article

Radiation therapy for gastrointestinal cancers is more precise and easier to tolerate due newer technologies and personalized care, according to experts.

Dr. Grivas Highlights Three Practice-Changing Trials in Bladder Cancer

April 17th 2025, 8:00pm

By Dr. Petros Grivas

Video

Dr. Petros Grivas discusses the importance of tailoring treatment decisions in bladder cancer based on data from three practice-changing phase 3 trials.

Antibody-Drug Conjugates Changed the Standard of Care in Bladder Cancer

April 17th 2025, 7:00pm

By Alex Biese

Article

Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, replacing single-agent treatments.

How I Manage When My Social Media Friends with Cancer Disappear

April 17th 2025, 5:00pm

By Debbie Legault

Article

I stay in the cancer social media world because it helps me cope, even when friends disappear and I’m left wondering if they’re resting, retreating or gone.

U.S. Centers Seek Namodenoson for Pancreatic Cancer Compassionate Use

April 17th 2025, 4:00pm

By Spencer Feldman

Article

U.S. medical centers are seeking FDA authorization for the compassionate use — or expanded access — of Namodenoson for patients with pancreatic cancer.

Emactuzumab Gets Fast Track Designation in Tenosynovial Giant Cell Tumors

April 17th 2025, 3:00pm

By Ryan Scott

Article

Emactuzumab has received fast track designation from the U.S. FDA for patients with tenosynovial giant cell tumors and who would not benefit from surgery.

Raising Awareness on Multidisciplinary Approaches in GI Cancers

April 17th 2025, 1:00pm

By Dr. Rachit Kumar

Video

Patients with gastrointestinal cancer may benefit from multidisciplinary care and open communication with their care team, as per an expert.

FDA sBLA Submitted for Anktiva Plus BCG in Papillary Bladder Cancer

April 16th 2025, 9:00pm

By Alex Biese

Article

A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

Breaking Down The Use of Rina-S in Advanced Ovarian Cancer

April 16th 2025, 8:00pm

By Dr. Elizabeth K. Lee

Video

Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.

TLX101 Demonstrated Efficacy in Recurrent High-Grade Glioma

April 16th 2025, 7:00pm

By Ryan Scott

Article

TLX101 therapy was efficacious in recurrent high-grade glioma, a type of brain cancer, according to preliminary results from the phase 2 IPAX-Linz study.

Sometimes, Distractions Help During Breast Cancer

April 16th 2025, 5:00pm

By Laura Yeager

Article

After a mammogram and breast cancer scare, a Broadway show provided a welcome distraction and joy, reminding me of life's beauty.

Bria-IMT Combo Outperforms Other Metastatic Breast Cancer Treatments

April 16th 2025, 4:00pm

By Spencer Feldman

Article

Bria-IMT plus check point inhibitors had a median overall survival which outperformed that of antibody-drug conjugates in HR+ metastatic breast cancer.

Bexmarilimab Plus Vidaza Elicit Responses in Myelodysplastic Syndromes

April 16th 2025, 3:05pm

By Ryan Scott

Article

Treatment with bexmarilimab and Vidaza elicited high overall response rates in both frontline and relapsed/refractory higher-risk myelodysplastic syndrome.